In today’s ACT Brief, we look at how AI and in-silico methods are reshaping drug repurposing, why staggered ICH GCP rollouts ...

ACT: As new ICH GCP guidelines roll out, how are sponsors balancing the drive for innovation—especially in areas like CAR-T ...

In today’s ACT Brief, we look at what’s fueling rapid growth in CNS and autoimmune research, why former FDA leaders are ...

Chen: Yes, obesity is experiencing accelerated growth over the last couple of years. According to our sister product Evaluate ...

The FDA has launched a secure, GovCloud-based agentic AI system to support regulatory workflows across review divisions, ...

For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...

In today’s ACT Brief, we look at new insights on strategy-driven clinical development, fresh survey data revealing persistent ...

In today’s ACT Brief, we examine how the FDA’s CNPV Program is reshaping operational planning and accelerated submission ...

In today’s ACT Brief, we examine how the CRA role is transforming alongside modern clinical trial technology, review the ...

Examine the rise of personalized and biomarker-driven therapies, the logistical challenges of rare patient populations, and ...

In this Q&A, John Kirk, principal regulatory specialist at Veristat, explains how the FDA’s Commissioner’s National Priority ...

With the right technology and support, CRAs can continue their evolution into powerful agents of trial success that bridge ...